


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18655

In Re Application Of: **Masato Kato, et al.**



Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

10/524,716

February 16, 2006

Amy E. Juedes

23389

1644

8342

Title: **METHOD OF IMMUNOMODULATION**

Address to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18655

In Re Application of: **Masato Kato, et al.**

APR 16 2007
PATENT EXAMINER
OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/524,716	February 16, 2006	Amy E. Juedes	23389	1644	8342

Title: **METHOD OF IMMUNOMODULATION**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

April 10, 2007
(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

Signature

Dated: April 10, 2007

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza-STE 300
Garden City, New York 11530
(516) 742-4343

CC: XZ:ab



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Masato Kato, et al.

Examiner: Amy E. Juedes

Serial No.: 10/524,716

Art Unit: 1644

Filed: February 16, 2006

Docket: 18655

For: METHOD OF IMMUNOMODULATION **Dated:** April 10, 2007

Confirmation No.: 8342

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Armitage, R. J. et al, "Evidence For A Functional Role Of CD83 In T- And B- Cell Responses", *Tissue Antigens* 48(4-2): 453 (1996), Abstract, NL-4-05, XP009077184;
2. Lechmann, M. et al., "The Extracellular Domain of CD83 Inhibits Dendritic Cell-mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells", *J. Exp. Med.* 194(12): 1813-1821 (2001);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 10, 2007


Xiaochun Zhu

3. Scholler, N. et al., "Cutting Edge: CD83 Regulates The Development Of Cellular Immunity", *Journal Of Immunology* 168: 2599-2602 (2002); and
4. Lechmann, M. et al., "Role of CD83 in the Immunomodulation of Dendritic Cells", *International Archives Of Allergy and Immunology* 129: 113-118 (2002).

The references were cited in a Supplementary European Search Report dated January 18, 2007 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. Please note that the reference cited in the Search report, namely, PCT International Publication No. WO 01/40308 A1, published June 7, 2001, was previously submitted in Applicants Information Disclosure Statement dated October 25, 2006. The relevance of the above-identified references has been described in the International Search Report.

Further, the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.


Respectfully submitted,



Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

XZ:ab

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT <i>(Use several sheets if necessary)</i> 		Atty. Docket No. (Optional) 18655	Application Number 10/524,716				
		Applicant(s) Masato Kato, et al.					
		Filing Date February 16, 2006	Group Art Unit 1644				
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
1.	Armitage, R. J. et al, "Evidence For A Functional Role Of CD83 In T- And B-Cell Responses", <i>Tissue Antigens</i> 48(4-2): 453 (1996), Abstract, NL-4-05, XP009077184						
2.	Lechmann, M. et al., "The Extracellular Domain of CD83 Inhibits Dendritic Cell-mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells", <i>J. Exp. Med.</i> 194(12): 1813-1821 (2001)						
3.	Scholler, N. et al., "Cutting Edge: CD83 Regulates The Development Of Cellular Immunity", <i>Journal Of Immunology</i> 168: 2599-2602 (2002)						
4.	Lechmann, M. et al., "Role of CD83 in the Immunomodulation of Dendritic Cells", <i>International Archives Of Allergy and Immunology</i> 129: 113-118 (2002)						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							